Timothy Whelan is a Respiratory physician affiliated with Medical University of South Carolina. OpenAlex indexes 43 publications with 2,360 citations (h-index 17); ClinicalTrials.gov lists 11 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
171 Ashley Ave
Charleston, SC 294258908
Telephone
843-792-1414Registry record last updated 30 Jul 2010.
Clinical trials
- A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)
Sponsor: Ontario Clinical Oncology Group (OCOG)
- Hypofractionated LocoRegional Radiotherapy in Breast Cancer
Sponsor: Ontario Clinical Oncology Group (OCOG)
- Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Sponsor: Canadian Cancer Trials Group
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20252 payments
- United Therapeutics CorporationProgram year20252 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20248 payments$10,083openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
28.4%Kinase inhibitor17.5%Ofev100%Part D≥18 patientsPyridone7.7%Pirfenidone100%Part D≥12 patients+ 1 more class in this area
Anti-infectives
18.1%Short-acting sulfonamides6.8%Sulfamethoxazole-Trimethoprim100%Part D≥16 patientsMacrolide Antimicrobial5.5%Azithromycin100%Part D≥12 patients+ 2 more classes in this area
Metabolism & gastrointestinal
16.4%Corticosteroid7.4%Prednisone100%Part D≥20 patientsProton pump inhibitor3.9%Pantoprazole Sodium100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Single Center Experience on Anti-Fibrotic (AF) Versus Immunosuppression (IS) in Connective Tissue-related Interstitial Lung Disease (CTD-ILD)
American Journal of Respiratory and Critical Care Medicine
2025 - A multidimensional classifier to support lung transplant referral in patients with pulmonary fibrosis
The Journal of Heart and Lung Transplantation
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Tanya Turan, MD
Medical University of South Carolina
Michael Zile, MD
Medical University of South Carolina
Don Rockey, MD
Medical University of South Carolina
William Creasman, MD
Medical University of South Carolina
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”